Published in Dig Dis Sci on January 01, 2002
ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol (2015) 1.58
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.94
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs (2010) 0.88
The medical management of primary sclerosing cholangitis. Medscape J Med (2008) 0.79
Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD. United European Gastroenterol J (2016) 0.76
Management Of Primary Sclerosing Cholangitis. Gastroenterol Hepatol (N Y) (2006) 0.75
A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis (2016) 0.75
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med (1999) 2.02
Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology (1991) 1.73
Primary sclerosing cholangitis. Hepatology (1999) 1.52
Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51
Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology (1983) 1.49
Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol (1999) 1.21
Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab (1998) 1.07
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int (1998) 1.06
The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology (1999) 1.05
Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol (1998) 1.04
Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol (1995) 1.02
Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl (1997) 0.97
Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol (1998) 0.91
Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol (1998) 0.87
Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone. J Lab Clin Med (1998) 0.80
Effects of pirfenidone and dermoid cyst fluid on adhesion formation. Fertil Steril (1998) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl (2002) 3.44
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
Results of the first year of the new liver allocation plan. Liver Transpl (2004) 2.86
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr (2004) 2.65
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant (2005) 2.54
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Improving liver allocation: MELD and PELD. Am J Transplant (2004) 2.14
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology (2005) 2.05
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology (2006) 1.87
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl (2003) 1.86
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation (2013) 1.78
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation. Liver Int (2008) 1.62
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl (2004) 1.58
MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology (2004) 1.57
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology (2013) 1.50
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant (2003) 1.46
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
The value of observational research in liver diseases. Hepatology (2011) 1.43
Feasibility of using a walking workstation during CT image interpretation. J Am Coll Radiol (2008) 1.41
Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol (2008) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps. Clin Gastroenterol Hepatol (2004) 1.34
MELD and other factors associated with survival after liver transplantation. Am J Transplant (2004) 1.34
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol (2002) 1.29
Noncathartic CT colonography with stool tagging: performance with and without electronic stool subtraction. AJR Am J Roentgenol (2008) 1.28
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl (2004) 1.19
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Evidence-based evolution of the MELD/PELD liver allocation policy. Liver Transpl (2005) 1.11
Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol (2003) 1.10
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis (2008) 1.09
Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl (2004) 1.08
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl (2002) 1.08
Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 1.07
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J Rheumatol (2005) 1.05
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (2005) 1.05
Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol (2011) 1.02
Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis (2006) 1.02
Evaluating sex and gender competencies in the medical curriculum: a case study. Gend Med (2012) 1.00
Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis (2002) 1.00
When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol (2003) 1.00
Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer (2008) 0.99
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2012) 0.99
Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 0.99
Characterization of lesions missed on interpretation of CT colonography using a 2D search method. AJR Am J Roentgenol (2004) 0.99
Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol (2010) 0.99
Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol (2007) 0.99